Hypertension is one of the most common co-morbidities of diabetes, accounting for about 30%-80% of diabetic patients; the coexistence of diabetes and hypertension significantly increases the risk of occurrence and progression of cardiovascular disease, stroke, nephropathy and retinopathy; therefore, controlling hypertension can significantly reduce the risk of occurrence and progression of diabetic complications. For patients with diabetic nephropathy, it is especially important to choose the right medication to control blood pressure and protect the kidneys. In most patients with diabetic nephropathy, antihypertensive treatment often requires a combination of drugs. In order to let patients better understand and use antihypertensive drugs, we have analyzed and introduced the commonly used antihypertensive drugs including angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor antagonists (ARB), calcium antagonists (CCB), beta-blockers and diuretics one by one. After research, ACEI and ARB have independent hypotensive nephroprotective effect, in the early stage of diabetic nephropathy, it can reduce urinary protein and delay the process of developing to end-stage nephropathy; when renal failure, the protective effect will be weakened, or even disappear, when the endogenous creatinine clearance rate is less than 30 ml/min generally no longer choose the drug. In addition, some patients taking the ACEI class of drugs will have an irritating dry cough. Therefore, it is important to monitor blood potassium and review renal function regularly when taking these two types of drugs; it is also worth noting that ACEI or ARB drugs are contraindicated in patients with combined renal artery stenosis and pregnancy. ACEI and ARB are the initial antihypertensive drugs or basic drugs for diabetes combined with hypertension, which have no effect on glucose and lipid metabolism, and the combination of the two has no significant therapeutic effect, therefore, the combination of the two is not recommended at present. CCB plays the role of vasodilator and blood pressure lowering by blocking calcium channels in vascular smooth muscle cells; it has no adverse effect on metabolism and its hypotensive effect is not affected by high salt diet, which is especially suitable for salt-sensitive hypertension in China. It has the function of protecting vascular endothelium and anti-atherosclerosis, and can be combined with ACEI or ARB to further delay the progress of diabetic nephropathy, but the drug also has some adverse reactions, the most common adverse reactions are facial flushing, ankle edema, palpitations, etc. Beta-blockers have potential adverse effects on glucose and lipid metabolism and may increase the incidence of new-onset diabetes mellitus. Even so, the combination of such drugs with diuretics may have adverse effects on glucose metabolism and should be avoided as much as possible. Diuretics are used to lower blood pressure through sodium excretion and reduce high blood volume load; thiazide diuretics are used when the glomerular filtration rate is greater than 30 ml/min, and tab diuretics are used when the glomerular filtration rate is less than 30 ml/min; however, electrolyte imbalance, hyperuricemia and disorders of glucose and lipid metabolism should be taken into consideration when taking these drugs, and small doses are recommended. In addition, these drugs are not recommended as the first-line treatment for diabetes mellitus with hypertension. If a glucose patient has a bad kidney, choose antihypertensive drugs carefully. In the selection of drugs, the efficacy, renal organ protection and safety, compliance and the impact on metabolism should be taken into account.